Oncology Research Review, Issue 91
In this issue:
Consolidation durvalumab may be a new standard for LS-SCLC
Amivantamab–lazertinib bests osimertinib in EGFR mutated NSCLC
Liposomal irinotecan promising for relapsed SCLC
Adebrelimab-chemo followed by thoracic radiotherapy for ES-SCLC
Lymph node involvement after CRT linked to worse rectal cancer outcomes
Perioperative chemoimmunotherapy strategy viable for stage 3A NSCLC
Capmatinib is an efficacious therapy for METex14 NSCLC
ICI–induced cardiotoxicity rare but can be fatal
PFS benefit to tislelizumab-chemo combo in unresectable NSCLC
Amivantimab tolerability improved with subcutaneous formulation
Expert contributor
Dr Alexander Davis
Dr Alexander Davis is a Medical Oncologist at Royal North Shore Hospital, North Shore Private Hospital and Genesis Care North Shore. He is currently undertaking a PhD in KRAS mutant lung cancers at the University of Sydney.
Latest Publications and Videos
Stay up to date with our latest clinical information.
Explore Research Review Publications and Videos
Dive into our publications and videos content from over 50 areas of medicine including Cardiology, Diabetes, Oncology, Haematology and Psychiatry.
Terms and Conditions
Website terms of use
By using our website, you agree to follow these terms and conditions.
Privacy policy
We take your privacy seriously. To understand how we collect, use, and protect your information, please read our Privacy Policy, which is part of these terms.
Copyright and use of website content
The content of our website is protected by copyright, trademarks, and other legal rights. You can: view, download, or print a single copy of content for your personal or professional use.
You cannot: copy, modify, or distribute website content, or use our website content for commercial purposes or in other works without permission.
Links to third-party websites
The Research Review website may link to third-party websites for your convenience. However:
We do not endorse or approve their products, services, or actions.
We are not responsible for their content or how they operate.
There is no formal partnership between us and third parties unless we clearly state otherwise.
Disclaimer and limitation of liability
We do our best to keep the information on our website accurate, but we do not guarantee that it is always correct or up to date.
To the fullest extent allowed by law, we are not responsible for:
Any loss, damage, or costs you may suffer from using (or being unable to use) our website.
Any decisions you make based on the information provided.
Any business losses, such as lost profits, lost data, or business interruptions.
Governing law
These terms are governed by New Zealand law. If there is a dispute, it must be resolved in a New Zealand court.